ONCODNA

History

Year	Detail
2012	Foundation of OncoDNA by Jean-Pol Detiffe, with the idea of making precision medicine a reality in oncology. The OncoDNA startup sets ground in Gosselies, Belgium, and counts a small team of just 5 employees.
2014	OncoDNA took its first steps in molecular profiling of advanced solid cancer with OncoDEEP, the pioneering biomarker test. It screens tumor tissue and assists oncologists in matching molecular tumor characteristics with suitable treatment options for patients.
2015	Launched OncoSHARE, an online platform that provides access to the clinical recommendations resulting from OncoDNA biomarker tests from all over the world.
2016	Introduced OncoSELECT, the first personalized liquid biopsy test available on the market. This test screens the circulating tumor DNA in blood samples to predict sensitivity or resistance to targeted therapies.
2017	Collaborated with BioSequence, a Spanish company specializing in cancer genomics. This collaboration resulted in the global commercialization of OncoKDM, a Software as a Service (SaaS) platform for NGS data interpretation.
2020	OncoDNA acquired IntegraGen, a leading French genomic services company. This collaboration combines their expertise to offer a wide range of services in laboratory testing, bioinformatics, and data interpretation for oncology and genetic diseases.
2022	OncoDNA introduces the OncoDEEP Kit, enabling in-house tumor profiling of solid tumors. With robust data analysis and clinical interpretation software, this solution identifies a wider range of treatment options for patients while reducing costs and reliance on outsourcing.